220 related articles for article (PubMed ID: 32668412)
1. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J; Zhang Y; Hu D; Gong T; Xu R; Gao J
Aging (Albany NY); 2020 Jul; 12(14):14271-14284. PubMed ID: 32668412
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
3. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
4. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
5. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
7. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
8. REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype.
Yu J; Liang Q; Wang J; Wang K; Gao J; Zhang J; Zeng Y; Chiu PW; Ng EK; Sung JJ
Oncogene; 2017 Jan; 36(2):182-193. PubMed ID: 27212034
[TBL] [Abstract][Full Text] [Related]
9. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
Xu X; Li Y; Zhang R; Chen X; Shen J; Yuan M; Chen Y; Chen M; Liu S; Wu J; Sun Q
J Ethnopharmacol; 2023 Jul; 311():116450. PubMed ID: 37023839
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive Gastric Cancer Circulating Tumor Cellular
Fan L; Chong X; Zhao M; Jia F; Wang Z; Zhou Y; Lu X; Huang Q; Li P; Yang Y; Hu Z; Li Q; Zhang X; Shen L
Anal Chem; 2021 Jan; 93(2):665-670. PubMed ID: 33314914
[TBL] [Abstract][Full Text] [Related]
12. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
13. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach.
Hagen SJ; Ang LH; Zheng Y; Karahan SN; Wu J; Wang YE; Caron TJ; Gad AP; Muthupalani S; Fox JG
Gastroenterology; 2018 Dec; 155(6):1852-1867. PubMed ID: 30195448
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
Shu Y; Zhang W; Hou Q; Zhao L; Zhang S; Zhou J; Song X; Zhang Y; Jiang D; Chen X; Wang P; Xia X; Liao F; Yin D; Chen X; Zhou X; Zhang D; Yin S; Yang K; Liu J; Fu L; Zhang L; Wang Y; Zhang J; An Y; Cheng H; Zheng B; Sun H; Zhao Y; Wang Y; Xie D; Ouyang L; Wang P; Zhang W; Qiu M; Fu X; Dai L; He G; Yang H; Cheng W; Yang L; Liu B; Li W; Dong B; Zhou Z; Wei Y; Peng Y; Xu H; Hu J
Nat Commun; 2018 Jun; 9(1):2447. PubMed ID: 29961079
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
[TBL] [Abstract][Full Text] [Related]
16. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype.
Sanada Y; Oue N; Mitani Y; Yoshida K; Nakayama H; Yasui W
J Pathol; 2006 Apr; 208(5):633-42. PubMed ID: 16435283
[TBL] [Abstract][Full Text] [Related]
18. High Expression of Retinoic Acid Induced 14 (RAI14) in Gastric Cancer and Its Prognostic Value.
He XY; Zhao J; Chen ZQ; Jin R; Liu CY
Med Sci Monit; 2018 Apr; 24():2244-2251. PubMed ID: 29654694
[TBL] [Abstract][Full Text] [Related]
19. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
Pereira MA; Ramos MFKP; Dias AR; Cardili L; Ribeiro RRE; de Castria TB; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076580
[No Abstract] [Full Text] [Related]
20. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer.
Kohmoto T; Masuda K; Shoda K; Takahashi R; Ujiro S; Tange S; Ichikawa D; Otsuji E; Imoto I
Gastric Cancer; 2020 May; 23(3):403-417. PubMed ID: 31654186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
